Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

825
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
825

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A modular hydrogel system with independent control of bioadhesion, fibrosis, and stiffness.

Science advances·2026
Same author

Oesophageal tissue screening system for assessing the retention and mucosal absorption of biologics.

Nature biomedical engineering·2026
Same author

The Use of Deep Learning in RNA Therapeutic Development.

ACS nano·2026
Same author

Am80-lipid nanoparticles serve as an enteric mucosal adjuvant following parenteral immunization with inactivated polio vaccine.

Science advances·2026
Same author

Author Correction: Extracellular vesicles incorporating retrovirus-like capsids for the enhanced packaging and systemic delivery of mRNA into neurons.

Nature biomedical engineering·2026
Same author

An appendiceal cancer organoid biobank identifies phenotypic evolution and druggable dependencies of peritoneal carcinomatosis.

Developmental cell·2026

Related Experiment Video

Updated: May 24, 2025

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

11.4K

Enhancing immunotherapy with tumour-responsive nanomaterials.

Stephen W Linderman1,2, Louis DeRidder3,4, Lucía Sanjurjo5,6

  • 1Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.

Nature Reviews. Clinical Oncology
|March 6, 2025
PubMed
Summary

Tumour-responsive nanomaterials offer targeted cancer immunotherapy delivery, overcoming systemic administration issues. These smart materials leverage the tumour microenvironment (TME) to enhance treatment efficacy and improve patient outcomes.

More Related Videos

Author Spotlight: Advancements in Nanoparticle Technology for Drug Delivery and Immunotherapy
05:06

Author Spotlight: Advancements in Nanoparticle Technology for Drug Delivery and Immunotherapy

Published on: November 10, 2023

886
Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

5.5K

Related Experiment Videos

Last Updated: May 24, 2025

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

11.4K
Author Spotlight: Advancements in Nanoparticle Technology for Drug Delivery and Immunotherapy
05:06

Author Spotlight: Advancements in Nanoparticle Technology for Drug Delivery and Immunotherapy

Published on: November 10, 2023

886
Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

5.5K

Area of Science:

  • Oncology
  • Nanomedicine
  • Immunotherapy

Background:

  • Systemic immunotherapy faces challenges like off-tumour toxicity and limited efficacy due to the immunosuppressive tumour microenvironment (TME).
  • Targeted delivery systems are needed to overcome these limitations and enhance therapeutic outcomes.

Purpose of the Study:

  • To review the development and application of tumour-responsive nanomaterials for targeted cancer immunotherapy.
  • To explore how TME characteristics can be leveraged for enhanced specificity and efficacy of nanomedicine-based immunotherapies.

Main Methods:

  • Review of preclinical research and clinical trials on nanomaterial-based immunotherapies.
  • Analysis of TME-specific triggers (pH, enzymes, hypoxia, etc.) for nanomaterial cargo release.
  • Evaluation of various immunotherapeutic agents delivered via nanomaterials (e.g., checkpoint inhibitors, cytokines, mRNA vaccines).

Main Results:

  • Nanomaterials designed to respond to TME cues show promise in targeted drug delivery.
  • Successful preclinical studies demonstrate enhanced efficacy and reduced toxicity.
  • Several approaches are advancing into clinical trials, indicating therapeutic potential.

Conclusions:

  • Tumour-responsive nanomaterials represent a significant advancement in cancer immunotherapy.
  • Leveraging TME dynamics offers a strategy to improve specificity and overcome treatment resistance.
  • Further research and clinical translation are crucial to realize the full potential of these innovative therapies for improved patient outcomes.